Related Experiment Video
Updated: Aug 6, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.9K
[Stroke, platelet activating factor and receptor antagonists]
Zhi-Guo Wang1, Dan-Qiao Wang1, Yue Jiao1
1Beijing Key Laboratory of Basic Research on Prevention and Treatment of Major Diseases by Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Summary
Platelet activation factor (PAF) receptor antagonists show promise for preventing and treating stroke, a major global health concern. This review details their classification, mechanisms, and drug characteristics for clinical guidance.
Area of Science:
- Cardiovascular Research
- Neurology
- Pharmacology
Background:
- Stroke is a leading cause of death and disability worldwide, necessitating effective prevention and treatment strategies.
- Antiplatelet aggregation therapies are crucial, with Platelet-Activating Factor (PAF) identified as a key mediator in stroke pathogenesis.
- The role of PAF in platelet aggregation highlights the potential of targeting its receptor.
Purpose of the Study:
- To review the classification of Platelet-Activating Factor (PAF) receptor antagonists.
- To elucidate the mechanisms of action for PAF receptor antagonists in cerebrovascular diseases.
- To summarize the characteristics of PAF receptor antagonist drugs for stroke prevention and treatment.
Main Methods:
- Literature review of existing studies on PAF receptor antagonists.
- Analysis of the role of PAF in the pathogenesis of stroke.
- Synthesis of information on the classification, mechanisms, and drug properties of PAF receptor antagonists.
Main Results:
- PAF receptor antagonists represent a significant area of research for stroke intervention.
- Understanding the classification and mechanisms is key to developing effective anti-PAF therapies.
- Drug characteristics of these antagonists are crucial for clinical application and further research.
Conclusions:
- PAF receptor antagonists offer a promising therapeutic avenue for stroke management.
- Further research and clinical application of these antagonists are warranted.
- This review provides a comprehensive overview to guide clinical practice and scientific investigation in stroke treatment.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.